Avascular Necrosis, Non-inflammatory Degenerative Joint Disease, Osteoarthritis, Post-Traumatic Osteoarthritis of Hip
Conditions
Keywords
Total Hip Replacement, Total Hip Arthroplasty, Hip Joint Replacement, Hip Prosthesis Replacement
Brief summary
This study is intended to gather medium (5- to 7-years) and long-term (minimum 8- to 10-years) information regarding the performance and safety of the commercially available 36mm CERAMAX® Ceramic on Ceramic (COC) Total Hip System from a cohort of study subjects that were previously enrolled in the IDE study. (COC = 36mm ceramic acetabular bearing insert component that articulates with a ceramic femoral head in the COC total hip replacement system)
Detailed description
Up to five (5) sites will participate. These sites participated in the IDE study and will continue subject follow-up. Subjects from the original IDE study (COC 36mm investigational subjects only) will be seen for a clinic visit at the time of consent (First visit at approximately 5 to 7 years post-op or 1825- 2919 days), and at minimum 8 years (2920-3649 days) , and minimum 10 years (3650-4015 days). Harris Hip evaluation, radiographic evaluation, subject hip-outcomes, and adverse event information will be collected at each visit. If a subject is not willing or able to return for a clinical and radiographic follow-up for either the minimum 8 year evaluation or the minimum 10 year evaluation, then a telephone interview may be utilized for the purpose of determining device survivorship.
Interventions
None listed
Sponsors
DePuy Orthopaedics
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Subjects who were previously enrolled in the COC 36 IDE study; * Individuals who are willing and able to provide informed patient consent for participation in the study; * Individuals who are willing and able to return for follow-up as specified by the study protocol; and * Individuals who are willing and able to complete the Subject Hip Outcomes questionnaire as specified by the study protocol.
Exclusion criteria
* In the opinion of the Investigator, the individual does not qualify if there are any concerns with the ability to follow the protocol specified evaluations. * Any component of the primary total hip was previously revised.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Device survivorship at 10-years post-operatively | 10-years post-operatively | Device survivorship will be estimated with a Kaplan-Meier survivorship analysis at 10-years post-operatively. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Harris Hip scores | Harris Hip score means and Harris Hip sub-score means will be estimated at the First visit at 5-7 years (1825- 2919 days); Minimum 8-years (2920-3649 days); Minimum 10-years (3650-4015days) | The Harris Hip score consists of five sub-scales: Pain, Function, Activities Deformity and Range of motion. The instrument is designed for completion by a clinician. |
| Subject Hip Outcomes | Subject Hip Outcomes will be estimated at the First visit at 5-7 years (1825- 2919 days); Minimum 8-years (2920-3649 days); Minimum 10-years (3650-4015days) | Subject Hip Outcomes is a standardized instrument for use as a measure of health outcome that is designed for completion by the study subject. This hips outcomes self-assessment includes five (5) questions about subject satisfaction and hip function. The 5 questions relate to study subject function, pain, need for pain meds, satisfaction and their status (i.e., better, same or worse). The percent of subjects who answer 'Yes' or 'Better' on each respective question will be reported. |
| Radiographic | At first visit (5-7 years), at Minimum 8-years (2920-3649 days); Minimum 10-years (3650-4015 days) | At 5 to 7 years, at Minimum 8-years and at minimum 10-years, secondary radiographic outcome measures will include high quality antero-posterior and lateral radiographs of the operative hip, which will be obtained during the same postoperative follow-up intervals as for the clinical evaluations. At the first enrollment visit (5-7 years), an additional Cross-Table Lateral films will be collected to permit assessment of cup positioning. Radiographic views will include: * AP Pelvis * AP femur * Lauenstein Lateral * Cross-Table Lateral (only at the first visit at 5-7 years) As a single composite radiographic outcome, the percent of subjects with radiolucencies greater than 2 mm in any zone, acetabular cup migration greater than 4 mm, change in cup inclination greater than 4 degrees or osteolysis at the time of last radiographic assessment will be reported. |
| Adverse Events | First visit at 5-7 years (1825- 2919 days); Minimum 8-years (2920-3649 days); Minimum 10-years (3650-4015days) | Subjects who consent to participate in this trial have already had their index surgery for implantation of the study hip; however, potential adverse events may still occur and will be captured at each follow-up visit. |
| Device survivorship | 5-years, 6-years, 7-years, 8-years, and 9-years | Device survivorship will be estimated with a Kaplan-Meier survivorship analysis at years 5 through 9 post-operatively |
Countries
United States
Outcome results
None listed